RICHMOND, Calif., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that it has signed a Memorandum of Understanding with SoldierSocks, a 501(c)(3) dedicated to working with veterans and veteran organizations. Over the next three years, SoldierSocks has established a goal of purchasing 80 Ekso GT™ robotic exoskeleton suits for VA Hospitals, organizations serving veterans, and eventually direct to veterans. This announcement represents an extension of Ekso Bionics'™ previous partnership with SoldierSocks, who earlier this year committed to purchasing ten suits, and expects to complete that commitment by year-end.
"SoldierSocks initially engaged Ekso Bionics to procure a 10-suit trial agreement. We were impressed by how they helped injured veterans walk again and continue to be impressed by their compelling technology," said Chris Meek, Co-Founder and Chairman of SoldierSocks. "Ekso Bionics' unique product offering and the level of interest from customers were determining factors in our decision to expand our partnership. We are proud to include their Ekso GT™ in our greater efforts to deliver a more independent and healthy future to our veterans who have returned home."
The Ekso GT is a uniquely designed wearable exoskeleton robotic suit enabling individuals with any amount of lower extremity weakness to stand up and walk over ground with a natural, full weight bearing, reciprocal gait.
To support the expansion, Ekso Bionics has tapped Mr. Josip Markus to serve as Director of National Accounts. Mr. Markus will oversee the SoldierSocks relationship and as well as develop new business with multi-system hospitals across the U.S. Mr. Markus brings with him nearly 20 years of experience in strategic relationship building, new business development in growth markets and partner network management, spanning financial, consumer goods and technology industries. Most recently, he was at Google, where he was in charge of Large Customer Sales.
"It is an exciting time for us to not only deepen our meaningful customer partnerships, but to expand from selling one or two devices to a customer to many devices to a customer. That we are delivering Ekso Bionics technology to VA Systems that help the men and women that have fought for our country is the cherry on top," said Nathan Harding, Co-Founder and CEO of Ekso Bionics. "Now that we are seeing this kind of acceleration in our medical device technology offering it allows us to become more pro-active in how we can expand to additional exoskeleton markets."
SoldierSocks, a 501(c)3 not-for-profit, was founded in 2009 to provide basic necessities such as baby wipes, socks and sunscreen to American soldiers fighting for our country in the trenches of Afghanistan and Iraq. As more of our soldiers return home to the U.S., SoldierSocks continues to assist our nation's heroes in re-acclimating to civilian life by providing scholarships for colleges and trade schools and offering paralyzed soldiers an opportunity to gain mobility outside of a wheelchair.
To support SoldierSocks in their efforts to provide services to veterans across the United States, please visit our website at www.SoldierSocks.com.
Phone: (888) 898-3235
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the Plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC at http://www.sec.gov. The Company does not undertake to update these forward-looking statements.
CONTACT: Media Contact: Chantal Beaudry, Managing Director Phone: 646-871-8480 email@example.com Investor Contact: Lauren Glaser, Vice President Phone: 646.378.2972 firstname.lastname@example.orgSource:Ekso Bionics